Multidose drug dispensing and discrepancies between medication records

Liv Johanne Wekre,1,2,3 Olav Spigset,4,5 Olav Sletvold,6,7 Janne Kutschera Sund,2 Anders Grimsmo1,3

ABSTRACT
Background The objective of this study was to investigate whether implementation of multidose drug dispensing (MDD) for elderly outpatients is associated with a change in the number of discrepancies in the medication record at the general practitioners (GPs) and at the community home-care services.

Methods A controlled follow-up study with paired design of patients’ medication records was performed during implementation of MDD. Medication records from the home care units and from the GPs were reviewed, and the discrepancies were noted. The discrepancies were rated into four classes based upon the potential harm, and a risk score system was applied, giving the potentially most harmful discrepancies the highest score.

Results Medication records from 59 patients with a mean age of 80 years were included. The number of discrepancies was reduced from 203 to 133 (p < 0.001), and the total risk score decreased from 308 to 181 (p < 0.001) after the implementation of MDD. For both drugs subject to MDD and drugs not suitable for MDD, the reductions in discrepancies were significant (39% and 31% reduction respectively).

Conclusions Calculated health risk due to discrepancies between the medication records from the home-care service and from the GPs decreased during the time of implementation of the MDD system. It seems likely that most of the positive effect was caused by the change in routines and enhanced focus on the medication process rather than by MDD per se.

INTRODUCTION
Incorrect use and incorrect handling of drugs is a major problem both in specialist care and in primary care.1 2 Even when limited to primary care, the number of adverse drug events has been seriously high in international studies.3–5 Both GPs and home-care services sense this problem and have expressed dissatisfaction with the collaboration regarding the medication of shared patients.6

In 1999, the Norwegian Board of Health initiated work on a plan of action aimed towards safer use of medicines. The focus was especially directed towards primary care services.7 A number of actions was suggested, one of which was the use of MDD in nursing homes and home-care services. MDD implies that patients receive their drugs machine-dispensed into one unit for each dose occasion, packed into disposable bags. The dose unit bags are labelled with patient data, drug contents data and time for intake.8–10

The number of MDD users is growing. In 2002, there were about 3000 MDD users in Norway; in 2006, the number had grown to 16 000 and in 2009 to approximately 35 000. Eighty per cent of the MDD users receive home-care service. There is an estimated potential of including a total of 200 000 patients from the primary care in Norway into the MDD system.11 12 MDD is expected to reduce medication errors, increase drug adherence and decrease waste of unused drugs.13–15 Still, more research is needed to document the effects of the system.12

Care of patients in their homes requires collaboration between GPs and home care providers who generally do not physically work together. Furthermore, GPs and home-care services maintain separate medication records for patients they have in common. In the MDD system, the pharmacy sets up one medication record for each MDD user, which is shared electronically with the company responsible for packing the multidose drugs. This record gives the pharmacist a complete overview of the patients’ drugs. It includes both drugs processed by the MDD system and drugs dispensed manually as before.

The aim of this study was to investigate whether the implementation of MDD for elderly outpatients was associated with a change in inconsistencies when comparing medication records from the GPs and the home-care services. We wanted to study both the number of discrepancies and the potential of the discrepancies to cause harm to the patients. To our knowledge, a controlled before–after study such as this has not been conducted before.

METHODS
Ten home care units in the city of Trondheim, Norway, each recruited up to 15 patients for participation, selecting the first 15 patients on an alphabetical list. The nurses responsible for the implementation of MDD in the units performed the selection and obtained informed consent.

Medication records from the GPs and from the home-care services were collected half a year before and 1 year after the implementation of MDD. After the implementation, medication records from the pharmacies responsible for delivering the MD packages were provided as well. The study ran from May 2006 to January 2008.

The primary outcome was discrepancies between the patients’ medication records at the GPs and at the home-care services, and the number of drugs in the GPs’ medication records. The discrepancies were rated for their potential to cause patient harm by a team consisting of two pharmacists, a GP, a clinical pharmacist and a geriatrician. Each member of the team made an individual assessment...
before the joint evaluation. In cases of disagreement about the inconsistencies, the issue was resolved by discussion. Consensus was reached in all cases. The team members were blinded with regard to whether the records were collected before or after MDD was implemented.

Assessment was done by a validated method, and discrepancies were rated into one of three classes according to whether they had minimal, moderate or severe potential to harm. In addition, we included a fourth class of non-classifiable discrepancies (table 1).

Discrepancies caused both by discordant prescriptions and by missing information in the medication records were registered. Two approaches were used to study whether there were any significant changes before and after the implementation of MDD:

1. Comparing the sum of risk scores belonging to the pair of medication records from the GP and from the home-care services, before and after implementation of MDD. The sum of risk scores was calculated by giving a class 1 discrepancy 1 point, a class 2 discrepancy 2 points and a class 3 discrepancy 3 points. Class 0 discrepancies gave no points.

2. Comparing the number of high-risk medication records before and after implementation of MDD. High-risk medication records were defined by the following criteria:
   a. Records where the sum of risk-scores was 6 or higher.
   b. Records containing one or more class 3 discrepancies.

The drugs were divided into three groups: (1) drugs subject to MDD, (2) drugs not suitable for MDD and (3) drugs prescribed to be used as required. By doing this, we were able to set up an internal control. We could study whether changes in the number of discrepancies were present among drugs subject to MDD only or whether the changes observed were independent of the MDD per se.

Analyses were completed using Microsoft Office Excel 2003 (Microsoft, Seattle, Washington) and SPSS (version 16; SPSS, Chicago, Illinois) for Windows. The statistical analyses used were the Student t test for paired samples for continuous data and the McNemar test for paired nominal data. p Values <0.05 were considered statistically significant.

### RESULTS

In total, 136 patients were included after the first collection of medication records. However, only 59 patients (43%) remained in the final material. The 77 drop-outs were as follows: 43 patients were not considered suitable for using MDD or did not receive home care when MDD was implemented, 20 patients had had MDD for a period of time but quit before the last collection of medication records, and 14 patients did receive MDD at the time of evaluation, but not all medication records were available (eight records missing from the GPs, three records missing from the home-care services and three records missing from the pharmacies). The patients had a mean age of 80 years at study start, ranging from 52 to 92 years. Forty-six (78%) of the patients were female. For comparison, the dropout patients had a mean age of 78 years, ranging from 54 to 98 years, and 56% were female.

The total number of drugs listed in the 59 medical records from the GPs was 386 before the implementation of MDD and 424 after the implementation (p=0.016). Before the implementation, there were 47 medication records (80%) with discrepancies, as compared with 45 records (76%) with discrepancies after the implementation (p=0.774).

In total, there was a 34% reduction in the number of discrepancies after implementation of MDD (p<0.001). The risk classification of the discrepancies is presented in table 2. For drugs subject to MDD, the reduction in the number of discrepancies was 59%, whereas for drugs not suitable for MDD (eg, injections, mixtures, eye-drops) and drugs to be used as required, the reduction was 51%. Table 3 shows the number of discrepancies for these three groups.

The various types of discrepancies are presented in table 4. The most frequent type of discrepancy both before and after implementation of MDD was that a prescription in the home-care services record was missing in the GP’s record. The second most frequent discrepancy was that a prescription in the GP’s record was lacking in the home-care services record.

For all the 59 pairs of medication records, there was a total risk score of 308 before the implementation and 181 after the implementation of MDD (p<0.001). There was also a significant

### Table 1 Classifications of discrepancies according to potential harm

<table>
<thead>
<tr>
<th>Class</th>
<th>Discrepancies unlikely to cause patient discomfort or clinical deterioration. An example would be prescription discrepancies in timing of the dose where this was considered unimportant, or discrepancies involving drugs considered not potent (eg, some vitamins).</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class</td>
<td>Discrepancies with the potential to cause moderate discomfort or clinical deterioration. An example would be a patient given a hypnotic drug every night by the home-care services, even though it was prescribed as required in the GP’s record.</td>
</tr>
<tr>
<td>Class</td>
<td>Discrepancies with the potential to result in severe discomfort or clinical deterioration. An example would be when warfarin was missing in one of the two records.</td>
</tr>
<tr>
<td>Class</td>
<td>It could not be decided with certainty whether the discrepancy was a true discrepancy or not. An example is lack of information on vitamin B12 injections in the home-care service records. This could result in a patient not receiving the injection (an error); alternatively could the injection each time be given at the GP’s office (no error). In the latter case, the information was not needed at the home-care services since they were not responsible for the administration of the drug.</td>
</tr>
</tbody>
</table>

### Table 2 Risk classification of discrepancies between the medication records from the general practitioners and from the home-care services before and after the implementation of multidose drug dispensing

<table>
<thead>
<tr>
<th>Potential harm*</th>
<th>No of discrepancies before implementation, N = 386</th>
<th>No of discrepancies after implementation, N = 424</th>
<th>Absolute reduction in the percentage of discrepancies (95% CI)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not classified (class 0)</td>
<td>12 (3%)</td>
<td>12 (3%)</td>
<td>0.29% (-1.15% to 1.73%)</td>
<td>0.690</td>
</tr>
<tr>
<td>Unlikely to cause discomfort (class 1)</td>
<td>84 (22%)</td>
<td>66 (15%)</td>
<td>6.66% (0.67% to 12.7%)</td>
<td>0.030</td>
</tr>
<tr>
<td>Potential to cause moderate discomfort (class 2)</td>
<td>97 (25%)</td>
<td>50 (12%)</td>
<td>12.3% (7.1% to 17.6%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Potential to cause severe discomfort (class 3)</td>
<td>10 (3%)</td>
<td>5 (1%)</td>
<td>1.54% (-1.87% to 4.95%)</td>
<td>0.369</td>
</tr>
<tr>
<td>Total</td>
<td>203 (53%)</td>
<td>133 (31%)</td>
<td>21.0% (11.8% to 30.2%)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

*See text for a detailed explanation of the risk classification procedure. †Number of prescriptions.
reduction in the number of high-risk medication records during the implementation of MDD (p<0.02) (table 5).

When the medication records at the GPs and at the home-care services were compared with the records from the pharmacies after implementation of MDD, we found 151 discrepancies. There were discrepancies between the pharmacy record and the GP record in 49 drug prescriptions and between the pharmacy record and the home-care services record in 133 drug prescriptions. In 31 drug prescriptions the pharmacy record neither agreed with the GP record nor the home-care service record.

**DISCUSSION**

Results from this study show a better agreement between the information in the medication records from the GPs and at the home-care services after the implementation of MDD compared with before the implementation. This improvement caused a drop in estimated health risks due to discrepancies in spite of a registered increase in the number of drugs in the medication records.

A significant reduction in the number of discrepancies was seen not only for the drugs subject to MDD, but also for the drugs not suitable for multidose dispensing (table 5). This finding supports the assumption that changes in routines constitute a central factor in the improvement and that the improvement is not necessarily due to the MDD alone. The improvement could be attributed to the implementation process itself, and to the work done by the different participants. The amount of allocated resources, the mandate from the city council to the implementation team and other routines adopted could also be of importance.

In previous Norwegian studies, it has been shown that up to 90% of the patients had one or more discrepancies in their medication records at the home-care services compared with the medication record at the GP,


Table 3  Number of discrepancies between the medication records from the general practitioner and from the home-care services before and after the implementation of multidose drug dispensing, classified on the basis of whether the drugs were dispensed in a multidose package or not

<table>
<thead>
<tr>
<th>Type of discrepancy</th>
<th>No of discrepancies before implementation, N = 203</th>
<th>No of discrepancies after implementation, N = 133</th>
<th>Absolute reduction in the percentage of discrepancies (95% CI)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multidose dispensable drugs</td>
<td>386 (100%)</td>
<td>203 (100%)</td>
<td>67.0% (32.5% to 89.2%)</td>
<td>0.0001</td>
</tr>
<tr>
<td>Drugs not suitable for multidose dispensing</td>
<td>15 (5%)</td>
<td>4 (3%)</td>
<td>72.0% (33.2% to 87.5%)</td>
<td>0.0069</td>
</tr>
<tr>
<td>Drugs to be used as required</td>
<td>9 (3%)</td>
<td>2 (1%)</td>
<td>76.0% (31.4% to 88.2%)</td>
<td>0.038</td>
</tr>
<tr>
<td>Total</td>
<td>457 (100%)</td>
<td>228 (100%)</td>
<td>54.0% (37.7% to 68.7%)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

†Number of prescriptions.

Table 4  Type of discrepancies between the medication records from the general practitioner and from the home-care services before and after the implementation of multidose drug dispensing

<table>
<thead>
<tr>
<th>Type of discrepancy</th>
<th>No of discrepancies before implementation, N = 203</th>
<th>No of discrepancies after implementation, N = 133</th>
<th>Absolute reduction in the percentage of discrepancies (95% CI)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prescription lacking in the record from the general practitioner</td>
<td>83 (41%)</td>
<td>49 (37%)</td>
<td>42.0% (20.7% to 57.9%)</td>
<td>0.001</td>
</tr>
<tr>
<td>Prescription lacking in the record from the home-care services</td>
<td>0 (0%)</td>
<td>29 (22%)</td>
<td>99.8% (99.2% to 99.9%)</td>
<td>0.001</td>
</tr>
<tr>
<td>Different dosage</td>
<td>30 (15%)</td>
<td>32 (24%)</td>
<td>6.0% (0.2% to 11.6%)</td>
<td>0.010</td>
</tr>
<tr>
<td>Fixed prescription versus prescribed as required</td>
<td>7 (4%)</td>
<td>4 (3%)</td>
<td>47.0% (12.3% to 71.7%)</td>
<td>0.040</td>
</tr>
<tr>
<td>Different dose frequency*</td>
<td>3 (1%)</td>
<td>6 (4%)</td>
<td>80.0% (32.0% to 93.0%)</td>
<td>0.0069</td>
</tr>
<tr>
<td>Missing information†</td>
<td>4 (2%)</td>
<td>7 (5%)</td>
<td>83.3% (33.3% to 98.1%)</td>
<td>0.031</td>
</tr>
<tr>
<td>Others</td>
<td>6 (3%)</td>
<td>6 (4%)</td>
<td>38.0% (3.0% to 71.9%)</td>
<td>0.048</td>
</tr>
<tr>
<td>Total</td>
<td>203 (100%)</td>
<td>133 (100%)</td>
<td>41.0% (24.0% to 56.0%)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

*Different dose frequency but the same total daily dose, for example 50 mg×2 versus 100 mg×1.
†Missing information about type of formulation or drug dose in the prescription.
the other hand, the MDD system may reduce the number of prescribers, which is an independent risk factor. 17 18

Limitations of the study

The dropout rate was large, 57%. Since the study population was old, and not all patients are suited for MDD, this was expected. Twenty patients (15%) in the dropout group had received MDD in a period of time before the follow-up. We cannot exclude with certainty that some of them may have died from reasons connected to the implementation of MDD, but we do not have any information that this did happen.

Use of multiple statistical testing can inflate the type I error rate, so some of the statistically significant findings could be spurious, and the small sample size means that some possibly important differences could have been missed.

We considered the selection of patients from an alphabetical list to be convenient. As the selection was done by the last names of the patients, the risk of drawing family members could be increased. However, the patients were recruited from 10 different home care units, and we do not consider that this procedure has introduced any relevant bias.

The implementation process in Trondheim precluded the possibility of including a control of patients not subject to MDD from the same municipality. Including an external control group would involve a different organisation prone to be influenced by other factors in the study period. Instead, we made an internal control by comparing drugs subject to MDD and drugs not suitable for MDD. Changes in the latter group should not be caused by the introduction of the MDD system per se, but if such changes occurred, they should be due to other elements common to both groups.

Access to clinical data could have made the classification of the discrepancies more reliable. 17 18 However, the classification used in this study has also been used by others based on drug information data alone 16 and is validated for use in settings like the present one.

The GPs and the home care units were informed about the study, thus giving them the opportunity to scrutinise the lists before they were forwarded to the study investigators. Before the implementation of the MDD system, the home care personnel collected the medication records from the GPs and handed them over to the study investigators together with their own medication records. This procedure gave them an opportunity to change their own medication records, thereby omitting discrepancies. After the implementation of MDD, the study investigators contacted the GPs and the home-care services separately. The home-care services and the GPs could then not compare their records directly, but they had, at least in theory, the chance to check their records against the records they receive from the pharmacy when changes are made in the multidose packages. However, since the home care units were asked for several (until 15) medication records, a double check could be time-consuming. Hence, we consider such a scenario unlikely.

Finally, any generalisation of findings in a study from one single administration and organisation should be done with caution, and this is also the case for the findings in this study.

Acknowledgements

We thank the GPs and the personnel at the home-care services and at the pharmacies for their time spent on the study. Thanks to Helge Garåsen and members of the council implementation group for the support given. We also acknowledge E Baulok Rischke, for her work with the study during her Master’s thesis, and Pål Romundstad, for help with the statistics.

Funding

Liaison Committee between the Central Norway Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU).

Competing interests

None.

Patient consent

Obtained.

Ethics approval

Ethics approval was provided by the Regional Committee for Medical Research Ethics (REK) and the Norwegian Data Inspectorate (NSD).

Provenance and peer review

Not commissioned, externally peer reviewed.

<table>
<thead>
<tr>
<th>Table 5</th>
<th>Number of high-risk medication records before and after the implementation of multidose drug dispensing (p&lt;0.02)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>High-risk medication record before implementation</strong></td>
<td><strong>High-risk medication record after implementation</strong></td>
</tr>
<tr>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Yes</td>
<td>8</td>
</tr>
<tr>
<td>No</td>
<td>6</td>
</tr>
<tr>
<td>Total</td>
<td>14</td>
</tr>
</tbody>
</table>

REFERENCES

Multidose drug dispensing and discrepancies between medication records

Liv Johanne Wekre, Olav Spigset, Olav Sletvold, Janne Kutschera Sund and Anders Grimsmo

Qual Saf Health Care published online August 4, 2010

Updated information and services can be found at:
http://qualitysafety.bmj.com/content/early/2010/08/04/qshc.2009.038745

These include:

References
This article cites 21 articles, 2 of which you can access for free at:
http://qualitysafety.bmj.com/content/early/2010/08/04/qshc.2009.038745#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/